DBV TECHNOLOGIE/S (NASDAQ:DBVT) had its price objective reduced by Bank of America from $33.00 to $30.00 in a research note published on Friday. They currently have a buy rating on the stock.
Several other equities research analysts have also issued reports on the stock. BidaskClub lowered shares of DBV TECHNOLOGIE/S from a sell rating to a strong sell rating in a research note on Wednesday, October 24th. Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a buy rating to a hold rating in a research note on Thursday, September 13th. Stifel Nicolaus assumed coverage on shares of DBV TECHNOLOGIE/S in a research note on Thursday, September 13th. They issued a buy rating and a $35.00 price objective for the company. Morgan Stanley reduced their price objective on shares of DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an equal weight rating for the company in a research note on Tuesday, September 11th. Finally, ValuEngine raised shares of DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Buy and a consensus target price of $33.67.
DBVT stock opened at $19.14 on Friday. DBV TECHNOLOGIE/S has a 1 year low of $16.65 and a 1 year high of $26.98. The firm has a market capitalization of $1.12 billion, a P/E ratio of -5.68 and a beta of 1.23.
Several hedge funds have recently made changes to their positions in DBVT. Dynamic Technology Lab Private Ltd acquired a new position in shares of DBV TECHNOLOGIE/S during the second quarter worth approximately $285,000. Exane Asset Management lifted its position in shares of DBV TECHNOLOGIE/S by 17.9% during the second quarter. Exane Asset Management now owns 50,000 shares of the company’s stock worth $964,000 after purchasing an additional 7,600 shares in the last quarter. First Midwest Bank Trust Division lifted its position in shares of DBV TECHNOLOGIE/S by 36.7% during the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock worth $2,642,000 after purchasing an additional 36,798 shares in the last quarter. Millennium Management LLC lifted its position in shares of DBV TECHNOLOGIE/S by 842.6% during the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock worth $3,074,000 after purchasing an additional 119,119 shares in the last quarter. Finally, BlackRock Inc. lifted its position in shares of DBV TECHNOLOGIE/S by 4.7% during the second quarter. BlackRock Inc. now owns 309,520 shares of the company’s stock worth $5,970,000 after purchasing an additional 14,032 shares in the last quarter. Institutional investors own 44.65% of the company’s stock.
About DBV TECHNOLOGIE/S
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Further Reading: What is the yield curve?
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.